Study Links DNA Methylation to FSHD Severity

Researchers at the University of Utah report that methylation at the DUX4 gene is associated with milder symptoms of a muscular dystrophy.

Updated on Nov. 17, 2026 in Tech

Study Links DNA Methylation to FSHD Severity

Researchers at the University of Utah linked higher DNA methylation at the DUX4 gene to milder symptoms of facioscapulohumeral muscular dystrophy, a disease that progressively weakens facial, shoulder and limb muscles. The findings were published in the journal Brain.

Why it matters

The results suggest that a measurable epigenetic marker may help explain why FSHD progresses differently between patients. The researchers say the findings could help predict disease outcomes and inform future treatment approaches.

The study combined historical clinical records with long-read sequencing of DNA samples stored since the 1980s across a nine-generation family. Whether the methylation pattern holds in broader patient populations has not yet been established.

The players

University of Utah

A public research university in Salt Lake City whose geneticists conducted the study on facioscapulohumeral muscular dystrophy.

The details

DUX4 becomes active in adulthood in people with FSHD, a process linked to a specific genetic change in the gene. Researchers developed a targeted long-read sequencing tool to measure methylation at DUX4 and found that participants with higher methylation were more likely to carry a DNA change near the gene HDGFL3.

Timeline

  1. November 17, 2026: Study published in Brain and reported by University of Utah Health.

  2. 1940s: The family began collaborating with University of Utah geneticists.

  3. 1980s: Earliest stored DNA samples in the study were collected.

Big Picture

The study extends a decades-long collaboration between a nine-generation family and University of Utah geneticists that began in the 1940s, shifting focus from the DUX4 genetic change itself to how its methylation state modulates disease severity.

For patients and families living with FSHD in Utah and elsewhere, the findings may eventually inform how disease progression is assessed. A clinical trial designed to increase methylation at DUX4 is already underway, with the first gene therapy patient treated weeks before publication.

The takeaway

Epigenetic markers such as DNA methylation may explain why people with the same genetic change experience very different disease courses. Tracking these markers could help clinicians anticipate outcomes for individual patients.

Further reading

For more on related advances, explore Biotech coverage across Utah.

Source note: This article includes information reported by News-Medical.